E112: luminelle is another surging FemTech startup that was recognized by VentureSouth for >100% YoY revenue growth, be it from a modest base. 2023 was a breakout year for luminelle because they completed all FDA medical device regulatory requirements, achieved 3rd party payor acceptance and gained provider acceptance as the new standard of care for office based uterine diagnostics without anesthesia using their patented micro hysteroscopy system. They are now focused on sales and developing a national partnership with an established industry incumbent. David interviews CEO Allison London Brown for an update on luminelle. She previously was on E56 in March of 2023 when she layed out the luminelle story. Today she's talking about the key events that enabled doubling revenue in 2023, why she expects to more than double revenue in 2024 and key sales developments that will propel luminelle to an exit. Watch the office procedure performed without anesthesia with the luminelle system. (recorded 3/27/24)
Follow David on LinkedIn or reach out to David on Twitter/X @DGRollingSouth for comments. We invite your feedback and suggestions at ventureinthesouth.com or email david@ventureinthesouth.com. Learn more about RollingSouth at rollingsouth.vc or email david@rollingsouth.vc. Follow Paul on LinkedIn. Download our White Papers and Cheat Sheets HERE. Thanks for listening and remember: Our mission is to MAKE MONEY, HAVE FUN AND DO GOOD.
E112: luminelle is another surging FemTech startup that was recognized by VentureSouth for >100% YoY revenue growth, be it from a modest base. 2023 was a breakout year for luminelle because they completed all FDA medical device regulatory requirements, achieved 3rd party payor acceptance and gained provider acceptance as the new standard of care for office based uterine diagnostics without anesthesia using their patented micro hysteroscopy system. They are now focused on sales and developing a national partnership with an established industry incumbent. David interviews CEO Allison London Brown for an update on luminelle. She previously was on E56 in March of 2023 when she layed out the luminelle story. Today she's talking about the key events that enabled doubling revenue in 2023, why she expects to more than double revenue in 2024 and key sales developments that will propel luminelle to an exit. Watch the office procedure performed without anesthesia with the luminelle system. (recorded 3/27/24)
Follow David on LinkedIn or reach out to David on Twitter/X @DGRollingSouth for comments. We invite your feedback and suggestions at ventureinthesouth.com or email david@ventureinthesouth.com. Learn more about RollingSouth at rollingsouth.vc or email david@rollingsouth.vc. Follow Paul on LinkedIn. Download our White Papers and Cheat Sheets HERE. Thanks for listening and remember: Our mission is to MAKE MONEY, HAVE FUN AND DO GOOD.